Flotation

Aprea Therapeutics, a Karolinska Institute spinout, is set to raise as much as $92m from an offering that would bank Karolinska Development a return of up to $8m.

Frequency Therapeutics, a regenerative medicine developer advancing MIT and Harvard research, has set the range for an initial public offering that will raise $107m if it floats at the high end.

Osage University Partners has celebrated an exit as migraine treatment developer Satsuma Pharmaceuticals listed on the Nasdaq Global Market following an $82.5m offering.

The immuno-oncology drug developer, spun out of Johannes Gutenberg University Mainz, has filed for a $100m offering in the US.

Karolinska Institute spinout Aprea Therapeutics has filed to raise approximately $68.3m in an IPO that will see it list on the Nasdaq Global Select Market.

Osage University Partners-backed Satsuma has filed for an $86.3m initial public offering that will fund phase 3 trials of its migraine candidate.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.